Did Qiagen beat or miss consensus estimates last quarter?

What were the key takeaways from Qiagen's earnings call?

What guidance did Qiagen's management provide for the next earnings period?

What is the market's earnings forecast for Qiagen next quarter?

What factors drove the changes in Qiagen's revenue and profit?

What is Qiagen's gross profit margin?

What does Qiagen do and what are its main business segments?

What is the revenue and EPS growth rate for Qiagen year over year?

- **Revenue Beat**: Q3 net sales $533M (+6%), core sales +6% CER. Adjusted EPS $0.61 vs. $0.58 target.
- **Strategic Moves**: $500M Parse acquisition for single-cell tech; $500M share buyback announced.
- **Profitability**: 29.6% operating margin, 9.2% R&D investment.
- **Key Growth Drivers**: QIAstat +11%, QuantiFERON +11%, QDI double-digit growth.
- **2028 Ambitions**: 7% CAGR, 31% margin on track despite headwinds.
- **Tariff Mitigation**: 90bps margin impact, but 2025 EPS EPS raised to $2.38.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 net sales rose 6% to $533 million (5% at constant exchange rates), with core sales up 6% CER. Adjusted EPS was $0.61, exceeding the outlook of $0.58.
- **Strategic Acquisitions**: Announced acquisition of Parse Biosciences for $500 million, expanding into single-cell analysis with instrument-free combinatorial barcoding technology. Also, a $500 million synthetic share repurchase set for January 2026.
- **Key Product Performances**: 
  - QIAstat diagnostics grew 11% CER, driven by 150 new placements and double-digit consumable growth.
  - QuantiFERON grew 11% CER, benefiting from latent TB conversion from skin tests.
  - Sample Technologies returned to growth (3% CER) on automated consumables demand.
  - QIAGEN Digital Insights (QDI) delivered double-digit growth, enhanced by Genoox integration.
- **2028 Ambitions**: On track for 7% CAGR in core sales and 31% adjusted operating margin by 2028, despite currency and integration headwinds.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted operating income margin of 29.6% (30% CER), absorbing 150bps of currency headwinds. R&D investment at 9.2% of sales, supporting new product launches.
- **Cash Flow**: Underlying operating cash flow of $466 million for 9 months, with free cash flow of $336 million.
- **Balance Sheet**: Strong cash position enabling $500 million share repurchase and $1 billion+ returns to shareholders by 2028. Leverage ratio expected to move towards industry average of 2x in 2026.
- **Tariff Impact**: U.S. tariffs creating 90bps headwind on gross margin, but mitigated through pricing and operational efficiency.

**【Q&A Highlights】**
- **Parse Acquisition**: Expected to be accretive by 2028, with $40 million revenue in 2026 and 3,000+ lab installations globally. Synergies with QDI for AI-driven single-cell data interpretation.
- **QIAstat Growth**: 11% Q3 growth despite seasonal softness, driven by GI and meningitis panels. U.S. placements in 6 months exceeded 2024 full-year volume.
- **Tariff Mitigation**: Surcharge pass-through successful, with no material demand delay. 2025 EPS guidance raised to $2.38 CER (+$0.10).
- **2026 Outlook**: Core sales growth 5-6% CER, adjusted EPS $2.38 CER. Shutdown impact on U.S. academic spending factored into Q4 guidance.

QGEN

QGEN fundamentals

You can ask Aime